ABVC BioPharma announces CFO resignation, CEO steps in as interim

Published 07/03/2025, 22:06
ABVC BioPharma announces CFO resignation, CEO steps in as interim

ABVC BioPharma, Inc. (NASDAQ:ABVC), a pharmaceutical company based in Fremont, California, with a market capitalization of $7.79 million, disclosed the departure of its Chief Financial Officer (CFO), Mr. Leeds Chow, on March 5, 2025. According to the 8-K filing with the Securities and Exchange Commission, Mr. Chow has resigned from his role, prompting the company to initiate a search for a new CFO. InvestingPro analysis indicates the company currently maintains a FAIR financial health score of 2.18.

In the interim, ABVC BioPharma’s Chief Executive Officer (CEO), Uttam Patil, will assume the additional responsibilities of CFO. The company has not provided specific reasons for Mr. Chow’s resignation but has confirmed that the transition is effective immediately. The leadership change comes as the company faces challenging market conditions, with revenue declining by 31% in the last twelve months.

ABVC BioPharma, previously known as American BriVision (Holding) Corp, operates within the pharmaceutical preparations sector under the industrial classification code 2834. The firm is incorporated in Nevada and has its executive offices located at 44370 Old Warm Springs Blvd., Fremont, CA 94538.

The company’s common stock is traded on The Nasdaq Stock Market under the ticker symbol ABVC. Currently trading at $0.64, the stock has shown mixed performance with a 7.85% gain year-to-date but a significant decline of 49.1% over the past year. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation. As of the date of the report, ABVC BioPharma has not indicated any changes to its business operations or strategic direction in light of the CFO’s departure. The company is scheduled to report its next earnings on March 14, 2025.

This announcement is based on the most recent 8-K filing from ABVC BioPharma with the SEC and reflects the company’s current administrative changes. Investors and stakeholders are advised to follow official releases from ABVC BioPharma for further updates regarding the appointment of a new CFO.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.